Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension

P Omvik1, E Gerdts, O L Myking

  • 1Institute of Internal Medicine, Department of Cardiology, Bergen, Norway. Per.Omvik@meda.uib.no

American Heart Journal
|September 30, 2000
PubMed

Insights

Losartan effectively lowers blood pressure in essential hypertension by reducing total peripheral resistance during rest and exercise. Cardiac function remains stable or improves, with significant left ventricular mass reduction in applicable patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Background:

  • Essential hypertension management often involves blood pressure reduction.
  • Long-term effects of losartan on central hemodynamics during rest and exercise remain unclear.

Purpose of the Study:

  • To investigate the long-term central hemodynamic effects of losartan in patients with essential hypertension.
  • To assess the impact of losartan on blood pressure, cardiac function, and left ventricular mass.

Main Methods:

  • A study involving 28 patients with essential hypertension treated with losartan (50-100 mg daily) for 8 months.
  • Intra-arterial pressure, cardiac index, heart rate, total peripheral resistance index, and stroke index were measured at rest and during 100 W exercise.
  • Twenty-four-hour ambulatory blood pressure and left ventricular mass were also assessed.

Main Results:

  • Losartan reduced resting blood pressure (165/102 to 145/91 mm Hg) and exercise blood pressure (193/104 to 179/96 mm Hg).
  • Total peripheral resistance index decreased by 12-15%, while cardiac index and heart rate remained unchanged.
  • Stroke index increased during exercise, and left ventricular mass decreased by 27% in patients with left ventricular hypertrophy.

Conclusions:

  • Losartan effectively lowers blood pressure by reducing total peripheral resistance at rest and during exercise.
  • Cardiac pump function is maintained or slightly improved with losartan treatment.
  • Losartan significantly reduces left ventricular mass in hypertensive patients with left ventricular hypertrophy.
Abstract

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...